Korean Circ J.  2018 Jul;48(7):537-551. 10.4070/kcj.2018.0166.

The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”

• Kang J
• Kim HS

• KMID: 2414890
• DOI: http://doi.org/10.4070/kcj.2018.0166

Abstract

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential after percutaneous coronary intervention (PCI), while many studies have focused on determining the optimal degree of platelet inhibition and optimal DAPT duration to minimize complications after PCI. Current guidelines developed by the American College of Cardiology/American Heart Association and the European Society of Cardiology summarize previous studies and provide recommendations. However, these guidelines are mainly based on Western patients, and their characteristics might differ from those of East Asian patients. Previous data suggested that East Asian patients have unique features with regard to the response to antiplatelet agents. On comparing Western and East Asian patients, it was found that East Asian patients have a lower rate of ischemic events and higher rate of bleeding events after PCI, despite a higher on-treatment platelet reactivity, which is referred to as the "East Asian paradox." As the main purpose of DAPT is to minimize ischemic and bleeding complications after PCI, these differences should be clarified before adopting the guidelines for East Asian patients. Therefore, in this article, we will review various issues regarding DAPT in East Asian patients, with a focus on the unique characteristics of East Asian patients, previous studies regarding antiplatelet agents in East Asian patients, and a guideline from an East Asian perspective.

Keyword

Dual antiplatelet therapy; Percutaneous coronary intervention; East Asians; Ischemic risk; Bleeding risk

MeSH Terms

Asian Continental Ancestry Group*
Aspirin
Blood Platelets
Cardiology
Heart
Hemorrhage
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors
Aspirin
Platelet Aggregation Inhibitors